David H.

I’d like to share thoughts on longevity clinics and also the future for the public longevity sector. First of all, it is good to see more longevity clinics around, including public clinics hosted by prominent public hospitals! Some prominent examples include Sheba Longevity Center (Ramat Gan, Israel), Healthy Longevity Clinic at Alexandra Hospital (Singapore), Mayo Clinic Healthy Longevity Clinic (Rochester, Minnesota, USA), the first public longevity clinic in the US. Private clinics are more abundant, for example Switzerland is home to several, including: 💼 Longevity Center (Zurich, Switzerland & Warsaw, Poland), managed by Joanna Bensz (co-founder,CEO), Prince Michael of Liechtenstein (co-founder). 💼 CLINIQUE LA PRAIRIE (Lake Geneva, Switzerland), managed by Simone Gibertoni (CEO), Adrian Heini (Medical Director) and with a starting price for the 1-week program to be around €50,000. 💼 AYUN (Zurich), managed by Dr. med. Leonie Bode and Vincent Aebi Several other clinics are located across Europe and in the UK: 💼HOOKE (London), managed by Kate Woolhouse (CEO), and Lev Mikheev (Founder), with average prices being €8.550 - €63.000. 💼Healthy Longevity Clinic (Prague, Czech Republic and Florida, USA), managed by Petr Sramek (CEO) 💼Lanserhof Lans (Austria, Denmark, Germany, the UK), managed by Christian Harisch (CEO) and with prices starting at €2,890 (Lanserhof Kur Classic, 7 nights) And US/Asia: 💼Human Longevity Clinic (San Francisco & San Diego, USA), led by Wei-Wu He, Ph. D. (Executive Chairman, Human Longevity, Inc.) and David Karow (Chief Innovation Officer) Evelyne Bischof, MD, PhD 💼CHI Longevity Clinic (Singapore), led by Andrea B. Maier (Co-founder, President of the Healthy Longevity Medicine Society ). I took prices from a report by Future of Health and I did not check them, so please do your own due diligence if you need. But the point is, they are not exactly super affordable for the broader community. That’s fine for now, and I am happy to see the progress in this area. But I see the future of public longevity a bit differently. IMO, it is not a “brick and mortar” way (going to clinic), but “in-house” way, where you have digital and biosensors, e.g. stool sensors, urine sensors, blood draw automation tools, digital trackers, and AI systems connecting the dots with the actual physician. I’m getting more investment requests for longevity clinical, but it is a challenging business. What matters for many is who is your longevity physician. It is important that organizations such as Healthy Longevity Medicine Society promote practical longevity stuff, and allow doctors to implement best practices in their usual medical routines, like diagnostics, personalized medicine etc. So, the future of longevity is not longevity clinics, I guess, although for now they are quite valuable for some patients. What do you think? #longevityindustry #longevityclinics #aging With Wei-Wu He, Ph. D.

152

22 תגובות

In 2020 I participated in a VC panel on the question "what would the doctors office look like in 10 years?" My answer: It would be in everything, it would be everywhere and it would no longer just be one place. Some may call this unified commerce, before that it was called omni channel, but I think of it as modularity. Because over the last decade, the concept of modularity has driven me. Where I asked myself how do we create one thing that can be reused or reapplied for dozens, hundreds, or even thousands of different use cases? I built Ease using the concept of modularity, and that's exactly how I'm building Cline, except this time I'm starting from scratch and 100% focusing on the patient. When I set out to solve the problem of private practice, I thought this; if we built more practices that were modular (i.e. different practice models, different payment models, different patient focuses, different communities), eventually there would be enough to spark a new SMB product environment that would level the playing field allowing private practices to eclipse our enterprise overlords, creating an entirely new wave of community focused innovation. It turns out that I was wrong, or perhaps I was too late, since the road to true modularity is long, hard, and expensive. Whatever the case, the overlords continue to to conquer, and despite a growing rebellion, if we truly want to shift whatever this version of healthcare is today we will need to restart with an entirely new strategy. I believe that this time around, it must begin with the patient. The question is, what tools can we give them to feel empowered, as well as engaged? How can we use technology to restore trust, how can we put access, knowledge, and treatment at the center of everything without losing efficacy or quality? How do we make the doctor's office no longer "a place" that people go but instead a place that goes wherever they go or is wherever they are? That's Cline, and that's the future we're looking to create. #HealthcareOnLinkedin

13

4 תגובות

👀 HOW DO WE GET DIGITAL HEALTH TO REFOCUS ON PREVENTATIVE CARE?👀 Enter Inbal Tirosh co-founder and CEO of the incredible Livez on this week's episode!! My favorite question to ask founders is what is your founding story? Tune in to hear Inbal explain her founding story, and how they are impacting patients lives and futures! Livez is built to make preventative care easy, convenient, and reduce claims. The Livez screening solution detect 85% of preventable diseases!! Reduces a whopping 75% of healthcare claims. How do they do this? Inbal jumps into it all with me, explaining, "All together if you take every person and they get a plan of what they need to get screened for, based on their individual profile, and their specific data, you can do that with fusion of big data, and you take them on a journey to prevent their predicted risks, based on family history and their own history and so on..." Then you automatically book them with follow up appointments. This is backed by health authorities, and by large insurers! Key Points 🗝 🌐 Livez screening solution covers more than 50 clinical domains and 120 screenings and vaccines, impacting 75% of healthcare claims. Livez is a preventive health platform that focuses on holistic screening and interventions to prevent chronic diseases. 🏥 The platform helps employers and health plans prioritize the health of their population by identifying health risks and guiding individuals towards appropriate interventions. This is an absolutely fascinating conversation about the new frontier of preventative care. Get on board, and tune in to this week's episode of the Digital Health Heavyweights Podcast Also- major teaser that their pricing is FULLY at risk. Why NOT? Learn more about preventative care, and how Digital Health is continuing to evolve!

53

10 תגובות

🚀 Meet Our Advisors! We are excited to highlight that Neil Littman, Founding Partner of Bioverge Ventures and Partner of Riverine Ventures, as one of the esteemed advisors in our #H7 accelerator program. 👉 We are open for application for the 2024 Cohort of H7 Healthcare Accelerator, powered by H7 BioCapital. Early Bird Applications are open until 💥 July 20th 💥! 🦄 Apply for the Program: https://shorturl.at/TfJdB 🦄 Apply to Become Advisor: https://lnkd.in/eSbGpX28  📅 Early Bird Deadline: July 20th, 2024 🎯 About H7 Accelerator Program: https://lnkd.in/g3ycA8eE ------- 🎯Get to know our top-tier accelerator advisor - Neil Littman "Neil Littman, M.S. is Founder & CEO of Bioverge Ventures, a venture capital firm exclusively dedicated to investing in #earlystage, #cuttingedge #healthcare companies. Bioverge’s investment thesis is focused on companies spanning the intersection of health + tech that are utilizing advances in technology to modernize healthcare, from bench-to-bedside." "Previously, Neil was Vice President of Business Development at Notable Labs, an oncology startup and Bioverge portfolio company, where he led the development of global corporate partnerships and contributed to the strategic vision of Notable as part of the Senior Leadership Team. Neil oversaw business development at Notable through the successful completion of the company’s $40 million Series B and was instrumental in negotiating multiple terms sheets to in-license clinical stage oncology assets." 🌷Apply now to learn invaluable insights from Neil Littman get connected with our 100+ industrial leading experts, pitch to top #investors, and scale your #startup! 🥳 Once you're selected for #H7 accelerator cohort, you'll be part of the #H7 community for life. Expand your business and expand your network with access to a talented group of founders, investors, mentors, and industry leaders. #accelerator #venturecapital #fundraising #healthcare #lifesciences #biotech #drugdevelopment #artificialintelligence #medicaldevices #hospitals #clinicaltrials #oncology #research #startup #founders #precisionmedicine #commercialization #sales

33

3 תגובות

A dome of innovation Last week was one of those rollercoaster rides we have unfortunately become accustomed to in Israel… while geopolitical adversity and profound human agony continued to cast a suffocating shadow, I found myself attending a half dozen gatherings and conferences focused on #HealthTech #innovation -- a shining celebration of ingenuity. At aMoon Fund, we've embraced Israel's entrepreneurial promise from inception; our team relishes encounters with innovators, startups and investment colleagues who are similarly devoted to building a transformational #HealthTech growth engine in #Israel and accelerating cure worldwide. To date aMoon Fund has invested over $250 million in 25 Israeli startups and organizations all focused on accelerating cure, and we're working on many more local investments. Last week was a testament to this commitment and passion. We started off on Monday at the annual conference of the Israel Society for HealthTech (#ISoH) where I moderated a panel of CEOs sharing stories of hardship as well as new strategic opportunities brought about by war. I was also joined by Noga Shiloach of Startup Nation Central who provided some stats on this past year’s investments and transactions in the Israeli startup ecosystem. On Tuesday, my colleague Dr. Yael Gruenbaum-Cohen hosted a lively panel on Healthcare investments and trends as part of Ernest and Young's #Journey conference, and on Tuesday afternoon, we convened a HealthTech #VC Happy Hour together with Sheba Medical Center, Tel Hashomer's ARC and UST discussing how US providers are embracing Israeli innovation despite challenging financial times. On Thursday, I joined friends from Microsoft and NVIDIA to discuss the promise and risks of #Gen.AI utilization in #healthcare, and how technology is poised to unlock patient access as well as better care, at a packed #ARC Summit. Why do I do this? Run around from one event to the next chatting on and off stage about the future of healthcare and the role of Israel in its digital transformation? Sure, it's part of the job, and granted it’s always nice to see friends and colleagues face to face. But truthfully, it's where I feel most impactful these days. As I think about the day after the war, and the world I am building for my 3 children, I want to make sure I do not regret a single moment of inaction. For my colleagues and me, the mission is global impact through local action; every new startup we are involved in, successfully treated patient, or dollar saved to a healthcare system, ensures that our fundamental belief and drive towards innovating care is shielded from attack, and that we will continue to thrive when a better tomorrow comes. Yair Schindel, MD, MBA, Tomer Berkovitz, Todd Sone, Moshic Mor, Yael Gruenbaum-Cohen, Reut Shema, Irena Katsman, Noah Lasson, Noam Waldoks, Gaby Hirsch

73

3 תגובות

2025 is going to be massive. That’s not just a belief; it’s my promise. I’m all in, doing whatever it takes to make it happen. Founders, this is for you — I know you are hungry to achieve your next milestone. Applications are open, and we’re here for one reason: to help you level up. You’ve got what it takes; now let’s take it further. Not a founder? You’re part of this too. Pass it on to someone who deserves a shot—you could be the reason their journey takes off. You may not feel this, but you are a giant and founders need to stand on your shoulders. Let’s make some noise!

15

1 תגובה

This week Mikal Ventures brings you a 2-week breakdown of the US capital market with an emphasis on the Mikal verticals. Over the 2-week period ending May 13, 450 new companies were added, with just under 95,000 companies included in the US Health Tech, Med Tech, Fin Tech, AI Tech, and Ed Tech verticals. AI Tech again saw the greatest percentage of growth in new companies and transactions, weighing in at over double the vertical averages for the period. The US Med Tech vertical led the way in SEC Filings, with Fin Tech leading in news articles. Mikal Ventures publishes these stats to provide a perspective on how the verticals and new startups move through time. We hope you find them informative and thought-provoking. VC Investors are always adjusting their "Play Book" with a variety of options for investing. Mikal Ventures is one of those alternatives, offering curated solutions to real world problems. Reach out if you have questions on how we can be of assistance and bookmark https://mikalventures.com/ for additional insights and information.

4

1 תגובה

📣 I’m proud to announce Springhood Ventures’ investment in NeoPrediX AG, a company committed to revolutionizing maternal and neonatal care through cutting-edge predictive analytics. 💡 Our decision to invest in NeoPrediX is driven by their groundbreaking approach to improving health outcomes during the most critical, formative days of life. By empowering clinicians with real-time, personalized insights, NeoPrediX enables proactive interventions that not only save lives but also elevate the quality of care for mothers and newborns. ✨ NeoPrediX is also tackling the urgent need for greater efficiency and productivity within hospitals. By streamlining processes and equipping healthcare providers with advanced tools, they are helping to reduce costs and improve operational outcomes—a win-win for both patients and healthcare systems. 🌟 📈 NeoPrediX aligns perfectly with Springhood’s mission to improve child health profitably and at scale. This partnership exemplifies the exceptional investment opportunities available in the child health sector. We are excited to collaborate with Thorsten Waloschek and the NeoPrediX team, and we look forward to their continued success in transforming this vital area of healthcare innovation. #SpringhoodVentures #NeoPrediX #investinkids #investinhumanity #mostimportantinvestment

113

11 תגובות

"Digital health is no longer the future; it is the present, reshaping our healthcare landscape in real-time." Excited to be part of the UCSF Digital Health Hub Foundation's Quarterfinalist Party! As a past board member, I'm honored to celebrate the outstanding quarterfinalists. As we reflect on the state of digital health in 2024, it's evident that the COVID-19 pandemic has fundamentally transformed healthcare delivery. The rapid adoption of telemedicine during the crisis has become a permanent fixture, with over 60% of physicians continuing to utilize this technology. The sprint towards smarter healthcare, catalyzed by necessity, has shattered preconceptions about digital-first health experiences. Virtual care is no longer a stopgap but an integral part of a seamless, anytime, anywhere health ecosystem. 🌍 We're witnessing the rise of B2B2C models in remote consultations, with companies like Teladoc Health and Amwell partnering with insurance providers to integrate their services into health plans. Public sector collaborations, like eConsult Health 's partnership with the NHS in the #UK, underscore the potential for remote consultations to enhance efficiency and accessibility at a national level. The digital health landscape is evolving rapidly, with advancements in remote consultations, mental health support, at-home diagnostics, and patient monitoring. AI and generative AI transform care delivery, making it more efficient, personalized, and patient-centric. 🤖 Yet, challenges remain. While venture capital funding for digital health has stabilized after the pandemic boom, it remains below its 2021 peak. Sectors like digital therapeutics face reimbursement hurdles, and we've seen major players like Walmart and Optum close telehealth businesses. Looking ahead, we anticipate further consolidation in digital health, driven by acquisitions to create broader ecosystems encompass telemedicine, mental health, and other specialized services. As healthcare leaders, we must leverage these digital advancements to improve access, enhance patient outcomes, and drive efficiency in our healthcare systems. The future of healthcare is digital, and the time to embrace this transformation is now. Congratulations to all the finalists! 🎉 Looking forward to the grand finale at #HLTH2024 in #LasVegas! 🙌 By the way, the pink drink that we were holding was delicious—and nonalcoholic! The Digital Health Hub Foundation - Digital Health Awards #HealthcareInnovation #DigitalHealth #UCSFHealthHub #Networking #HealthTech #Entrepreneurship #LasVegasFinale Walter Greenleaf, PhD Daniel Kraft, MD Unity Stoakes StartUp Health University of California, San Francisco UCSF Innovation Ventures American Association for Precision Medicine (AAPM) WISE World Investors & Entrepreneurs Society #AAPMhealth #aapm_health

94

7 תגובות

Venture Capital in Healthcare : Catalyzing Medical Breakthroughs Venture capital plays a pivotal role in shaping the future of medicine, acting as a crucial catalyst for innovation and advancement in healthcare. As a physician deeply involved in the VC world, I've witnessed firsthand how strategic investments are driving forward remarkable medical breakthroughs that promise to revolutionize patient care. So, why is VC Essential in Healthcare? Funding Innovation: Many groundbreaking ideas in medicine require substantial financial backing to move from concept to clinic. Venture capital provides the necessary resources to support early-stage innovations that might otherwise struggle to find funding through traditional channels. Speeding Up Development: VC investment can significantly accelerate the development process of new medical technologies and pharmaceuticals. By providing capital, expertise, and resources, VC helps companies navigate complex regulatory paths and reach the market faster than they could on their own. Bridging the Gap: There is often a 'valley of death' in medical innovation, where projects fail to move from research to development due to lack of funding. VC bridges this gap, turning viable research into actionable, market-ready solutions. The influence of venture capital on healthcare extends beyond just financial investment. It fosters a dynamic ecosystem where: Innovative Approaches are nurtured, enabling technologies like AI, precision medicine, and telehealth to flourish, each opening new avenues for enhancing patient care. Entrepreneurial Spirit thrives, encouraging medical professionals and researchers to develop and pitch new solutions that address unmet needs. Strategic Partnerships between startups and established healthcare entities are formed, integrating fresh ideas into mainstream medical practice. Looking Ahead 👇 As we look to the future, the synergy between venture capital and healthcare holds immense potential. With continued VC support, the next decade could see monumental advancements in how we diagnose, treat, and manage diseases, making previously unthinkable levels of patient care a reality. Let's discuss how we can further harness the power of VC to transform healthcare landscapes and improve patient outcomes globally. #HealthcareVC #MedicalInnovation #FutureOfMedicine ----- Click the link in my bio to join 2,000+ healthtech experts and thought leaders.

36

2 תגובות

The Israeli tech sector accounts for 20% of the country's economic output, and continues to attract #VC investment… despite the war, the Israeli tech train keeps moving. But... is it sustainable? From the outside looking in, many saw #Israel as the golden child over the past 10 years… but now, there’s doubt it’ll continue. Yes, cyber and AI continue to attract capital, including foreign money, but it comes at a cost. Many VCs are asking founders to move to the US quicker, hire more in the US vs. in Israel, and to do whatever it takes to lower the risk. Early-stage startups are finding it harder to secure investments, and the war has disrupted operational continuity for many companies. Yet, hard times create big companies, and the challenges Israeli founders are faced with today will pave the way for a new wave of successful companies in the future. Where do we go from here? Israeli founders have demonstrated extraordinary resilience, but the path forward is uncertain… 97212 Ventures PitchBook #startupnation #israelunderfire #venturecapital

39

1 תגובה

🚀 Breaking News: We're Investing in the Future of Healthcare with Curexel Technologies! 🚀 Am happy to announce our first "zero-to-one" stage investment in Curexel Technologies (https://curexel.com/), a groundbreaking company at the forefront of healthcare innovation. Some of the firsts in this deal, as an early stage investor are: · First investment in #Healthcare devices · Worked zero-to-one stage with founders · Working with the founders on product feasibility, manufacturing partners, distribution partners and overall GTM of the product · Partnered with Asutosh Upadhyay as a co-investor for this deal who brings a wealth of experience in early stage investing and global partner network · Engaged with legal adviser Disha Toshniwal for setting up the company legal framework, cap table etc for us to come onboard with the #firstcheque What is Curexel solving? Curexel's vision is to accelerate medical device based research and build patents towards development of novel drug delivery products and engage with industry to enable distribution and commercialization. The first product is to build an "Intradermal Painless Injection" device which will solve for unreliable delivery, pain induced due to tangential insertion and high degree of skill required by the nurse, using current injection devices. Top 3 key use cases for intradermal injection devices are:  1.    Vaccinations: Intradermal injections are used for certain vaccines, including the Bacillus Calmette-Guérin (BCG) vaccine for tuberculosis and certain influenza vaccines. 2.    Allergy Testing: Intradermal testing is common for detecting allergies in children. This method allows for precise administration of allergens to observe reactions safely. 3.    Local Anesthesia: Intradermal injections are often used to administer local anesthetics before minor procedures or intravenous insertions. Market Opportunity: The global intradermal injection market size was valued at US$3.8 Billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 10.8% from 2022 to 2032 We look forward to supporting Curexel founders Kedar Badnikarvasudha nShreyas N J in their mission to bring innovative and painless drug delivery products for consumers worldwide. If you are keen to partner with Curexel in this journey or if you are keen to invest in their upcoming pre-seed round, please DM. Stay tuned for more updates on this exciting journey! #medicaldevices #healthcare #medicine #enterpreneurship #innovation #startups #venturecapital #investing #technology

89

8 תגובות

At Two Bear Capital our definition of value-add, lead, early-stage investing is to form a true partnership with the founders we back. We believe that only a small fraction of our return potential comes from us “picking right” when we make our first investment into a company – the vast majority comes from how effectively we can actively help our brilliant founders over the ensuing 3-7 years in achieving the passionate, ambitious, and positive-impact goals that drive them.

22

1 תגובה

🚀 Great to see SiPhox Health, one of our portfolio companies, featured in MIT News! The article captures how SiPhox is attempting to revolutionize home-based blood testing with cutting-edge silicon photonic technology. We co-invested in SiPhox through LongeVC back in 2023, alongside Intel Capital (leading the Series A), Khosla Ventures , and other prominent investors, because we recognized the disruptive potential of this technology. I think SiPhox’s approach to diagnostics is not just an incremental improvement—it’s a leap forward in accessibility, precision, and scalability. Here is my take what stands out in the SiPhox’s story: ✔️ Miniaturization of Lab-Grade Diagnostics: SiPhox has condensed what traditionally required large optical lab equipment into a single silicon photonic chip, leveraging advances in integrated optics and semiconductor manufacturing. ✔️ Scalability Through Silicon Photonics: Their chip fabrication can scale to produce billions of disposable chips per month using standard semiconductor fabs, enabling cost-effective, high-volume production. ✔️ Seamless Patient Experience: The "Nespresso-like" blood testing system integrates third-party blood sample collection (e.g., arm patches) with a reusable device and disposable cartridges, providing an intuitive, at-home diagnostic solution. ✔️ High-Fidelity Results: SiPhox's photonic immunoassay sensors offer lab-grade precision, tracking critical biomarkers for chronic disease management directly from home. ✔️ Platform Potential: Beyond diagnostics, SiPhox’s ecosystem offers integration with telehealth providers and third-party health services, paving the way for an Apple App Store-like platform for healthcare. This is healthcare democratization in action, making regular health monitoring as simple as brushing your teeth. Also, Kudos to Zach Winn of MIT for capturing this innovation so well. The future of healthcare is here, and we couldn’t be prouder to support SiPhox on this journey. 💡 Check out the article in the comments 👇 Image credit: MIT News and SiPhox Health

78

3 תגובות

This week Mikal Ventures brings you a 4-week breakdown of the US capital market with an emphasis on the Mikal verticals. Over the 4-week period ending April 15, just over 900 new companies were added, with 94,109 companies included in the US Health Tech, Med Tech, Fin Tech, AI Tech, and Ed Tech verticals. AI Tech again saw the greatest percentage of growth in new companies and transactions, weighing in at over double the vertical averages for the period. The US Fin Tech vertical again led the way in SEC Filings and news articles. Mikal Ventures publishes these stats on a rolling 4-week basis to provide a perspective on how the verticals and new startups move through time. We hope you find them informative and thought-provoking. VC Investors are always adjusting their "Play Book" with a variety of options for investing. Mikal Ventures is one of those alternatives, offering curated solutions to real world problems. Reach out if you have questions on how we can be of assistance and bookmark https://mikalventures.com/ for additional insights and information.

3

3 תגובות

A quantum leap step for Medlumics’ Ablaview to transform afib treatments by offering the first ever qualitative and quantitative real time lesion assessment during RF and PFA catheter ablation procedures.

16

After $400M of capital invested and 30 portfolio companies in health and pharma tech, we are excited to publish our SignalFire health and pharma tech sector thesis, 2024 edition and beyond! 👊 Here are 5 major trends that we're focused on 📈 If you are a founder building in any of these categories below, we'd love to hear from you! 1) Explosion of healthcare data creates both opportunities & risks in the GPT-4 era 2) PharmaTech is accelerating R&D, manufacturing & distribution to tackle inefficiencies 3) The labor shortage crisis and the need for AI to improve productivity 4) Aging population and the shift to hybrid, value-based care models in patients’ homes  5) Scaling access to lifesaving therapeutic breakthroughs: GLP-1s & CGTs Grateful to work closely with an incredible team focused on this sector including our legendary Eric Larsen, and partners in crime Sooah Cho, Tony Pezzullo, Sahir Raoof, Adele English 🙏 What gets me up every morning is our incredible portfolio, each of which making their own dent in our healthcare system for the better — Grow Therapy, Color, Ro, CodaMetrix, Health Gorilla, Verse, Wellth, PayZen, Recora, all.health, Bicycle Health, Form Health, Health Note, Osso VR, Praia Health, Freshpaint, Auxilius, Ovation, OrthoFX, Moxie and many others coming out of stealth soon 🚀 #healthtech #pharmatech #sectorthesis #innovation https://lnkd.in/gDE3nQqK

329

37 תגובות

Shameless self-promotion alert 😁 It’s quite hard for fund managers to talk about their fund, but in today’s busy market it’s part of the game... For me, it’s always about letting #founders talk about our work rather than us praising ourselves. Recently, I got the chance to chat with Pulse 2.0, where I had the opportunity to discuss 97212 Ventures, our mission, and our commitment to investing in top early-stage Israeli startups with a New York state of mind. At 97212, we’re all about moving early-stage Israeli #startups from zero to one, while working hard with Israeli founders on building their businesses in the US and unlocking their full potential. It’s a long journey, and we love being there at the earliest stages to help founders crawl, walk, and run. More about the evolution of our fund, and what makes us tick below. #foundersjourney #venture capital #nyctech

92

Yesterday, we had the pleasure of attending the Road2 Haifa Bioconvergence for Startups event, where Gil Kerbs, who heads our new investments, participated in the VC panel. 🌟 One key message he shared was that when it comes to bio convergence in healthcare (rather uniquely as compared to other areas), there are many companies in which the concern about the potential market is minimal - if your technology to cure a type of cancer actually works, there are minimal concerns about who would buy it.  Therefore, when entrepreneurs of such companies approach investors, they need to understand how much time, data, and money it will take to verify and prove their technology, and translate it into a fundable milestones - as that would be the #1 concern of investors. 🎯🔬

24

4 תגובות